All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F07%3A00003982" target="_blank" >RIV/61989592:15110/07:00003982 - isvavai.cz</a>

  • Alternative codes found

    RIV/62157124:16370/07:00001085

  • Result on the web

  • DOI - Digital Object Identifier

Alternative languages

  • Result language

    angličtina

  • Original language name

    Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia

  • Original language description

    Background Adipocyte-fatty acid binding prottein (A-FABP) is a circulating protein expressed in adipocytes and macrophages. Several recent studies deminstrated that A-FABP might be involed in the pathogenesis of metabolic syndrome, particularly in dyslipidaemia, insulin resistance and atherosclerosis. The aim of this study was to investigete the influence of atorvastatin treatment (20 mg day for 3 months) on serum A-FABP value in subjects with hyperlipidaemia. Conclusions In conclusion, our study confirmed in vivo that atorvastatin reduces serum A-FABP by a pleiotropic mechanism and supports the hypothesis that A-FABP is involved in atherosclerotic actions.

  • Czech name

    Léčba atorvastatinem redukuje sérové hodnoty "adipocyte-fatty acid binding" protteinu u pacientů s hyperlipidémií

  • Czech description

    A-FABP je cirkulující protein exprimovaný v adipocytech v makrofázích. Současné studie uvádějí, že A-FABP by mohl mít roli v patogenezi metabolického syndromu, především v rozvoji dyslipidémie, inzulínové rezistence a aterosklerózy.

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    ED - Physiology

  • OECD FORD branch

Result continuities

  • Project

    <a href="/en/project/1A8250" target="_blank" >1A8250: Frequency and Distribution of Insulin Resistance as a Risk Factor for Cardiovascular and Metabolic Diseases</a><br>

  • Continuities

    S - Specificky vyzkum na vysokych skolach

Others

  • Publication year

    2007

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    European Journal of Clinical Investigation

  • ISSN

    0014-2972

  • e-ISSN

  • Volume of the periodical

    8

  • Issue of the periodical within the volume

    37

  • Country of publishing house

    GB - UNITED KINGDOM

  • Number of pages

    6

  • Pages from-to

    637-642

  • UT code for WoS article

  • EID of the result in the Scopus database